Dose Adult- NB; individualisation is critical because of its low therapeutic index
Usual dosage ranges: I.M., I.V.: Conventional: 1-2.5 mg/kg/dose every 8-12 hours; (75-150 mg / day)
To ensure adequate peak concentrations early in therapy, higher initial dosage may be considered
in selected patients when extracellular water is increased (edema, septic shock, postsurgical, or trauma)
Once daily: 4-7 mg/kg/dose once daily;
some clinicians recommend this approach for all patients with normal renal function;
this dose is at least as efficacious with similar, if not less, toxicity than conventional dosing
Intrathecal: 4-8 mg/day
Indication-specific dosing: I.M., I.V.:
Brucellosis: 240 mg (I.M.) daily or 5 mg/kg (I.V.) daily for 7 days; either regimen recommended in combination with doxycycline
Cholangitis: 4-6 mg/kg once daily with ampicillin
Diverticulitis (complicated): 1.5-2 mg/kg every 8 hours (with ampicillin and metronidazole)
Endocarditis: Treatment: 3 mg/kg/day in 1-3 divided doses
Meningitis Enterococcus sp or Pseudomonas aeruginosa:
I.V.: Loading dose 2 mg/kg, then 1.7 mg/kg/dose every 8 hours (administered with another bacteriocidal drug)
Pelvic inflammatory disease: Loading dose: 2 mg/kg, then 1.5 mg/kg every 8 hours
Alternate therapy: 4.5 mg/kg once daily
Plague ( Yersinia pestis ): Treatment: 5 mg/kg/day, followed by postexposure prophylaxis with doxycycline
Pneumonia, hospital- or ventilator-associated: 7 mg/kg/day (with antipseudomonal beta-lactam or carbapenem)
Synergy (for gram-positive infections): 3 mg/kg/day in 1-3 divided doses (with ampicillin)
Tularemia: 5 mg/kg/day divided every 8 hours for 1-2 weeks
Urinary tract infection: 1.5 mg/kg/dose every 8 hours
Dosing: Pediatric
7.5mg/kg OD if >7days old.
Neonatal; <2kg=3mg/kg OD {=} >2kg 5mg/kg OD
Use of ideal body weight (IBW) for determining the mg/kg/dose appears to be more
accurate than dosing on the basis of total body weight (TBW).
In morbid obesity, dosage requirement may best be estimated using a dosing weight of IBW + 0.4 (TBW - IBW).
Initial and periodic plasma drug levels (eg, peak and trough with c
onventional dosing) should be determined, particularly in critically-ill patients with serious infections
or in disease states known to significantly alter aminoglycoside pharmacokinetics
(eg, cystic fibrosis, burns, or major surgery).
Usual dosage ranges: I.M., I.V.:
Infants and Children <5 years: 2.5 mg/kg/dose every 8 hours*
Children ≥5 years: 2-2.5 mg/kg/dose every 8 hours*
*Note: Higher individual doses and/or more frequent intervals (eg, every 6 hours)
may be required in selected clinical situations (cystic fibrosis) or serum levels document the need.
Indication-specific dosing:
Meningitis: Neonates: I.V.:
0-7 days of age: <2000 g: 2.5 mg/kg every 18-24 hours; >2000 g: 2.5 mg/kg every 12 hours
8-28 days of age: <2000 g: 2.5 mg/kg every 8-12 hours; >2000 g: 2.5 mg/kg every 8 hours
Brands.
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Bactigen | FDC. Ltd | Wessex Pharmaceuticals Limited | 0.30% | 5ml | eye drops | per ml | KES 40 |
| Beagenta | ICI Pakistan | Surgipharm Ltd | 0.30% | 10ml | eye drops | per ml | KES 75 |
| Colircusi Gentamicin | Cusi Alcon | Pan Pharmaceuticals Ltd | 0.30% | 10ml | eye drops | per ml | KES 260 |
| Garamycin | Schering-Plough (See also Essex Chemie) | Laborex Kenya Eurapharma Ltd | 0.30% | 10ml | eye drops | per ml | KES 297.00 |
| Garamycin | Schering-Plough (See also Essex Chemie) | Laborex Kenya Eurapharma Ltd | 15gm | Cream | KES 324 | ||
| Garamycin | Schering-Plough (See also Essex Chemie) | Laborex Kenya Eurapharma Ltd | 15gm | Ointment | KES 324 | ||
| Gentasone | Caplin Point Lab Ltd. | Medisel Kenya Ltd | 10ml | eye drops | per ml | KES 15 | |
| Gentosep | Beximco Pharma | Madawa Pharmaceuticals Ltd. | 3mg | 15gm | Cream | KES 143.00 | |
| Ivygentacin | Ivee Aqua EPZ Ltd. | Harley's Limited | 0.30% | 10ml | eye drops | per ml | KES 17.00 |
| Medigenta | Medivet Products Ltd | Medivet Products Ltd. | 15gm | Cream | KES POR | ||
| Wencin | West Coast Pharmaceuticals Works Ltd | Ray Pharmaceuticals Ltd | 10ml | eye drops | per ml | KES 26.25 | |
| Oftamolosa Cusi Gentamycin | Cusi Alcon | Pan Pharmaceuticals Ltd | 10 | Tablet | per tablet | KES 65.7 | |
| Oftamolosa Cusi Gentamycin | Cusi Alcon | Pan Pharmaceuticals Ltd | 0.30% | 5g | Ointment | KES 360.00 | |
| Dawagenta | Dawa Limited | Dawa Limited | 80mg | 2ml | Injection | KES 5.00 | |
| Genacyn | Square Pharmaceuticals Ltd | ACE Pharmaceuticals Ltd | 20mg | 10 | Injection | per ml | KES 130.00 |
| Genacyn | Square Pharmaceuticals Ltd | ACE Pharmaceuticals Ltd | 80mg | 10 | Injection | per vial | KES 180.00 |
| Gentacil | Globe Pharmacy Ltd., | Globe Pharmacy Ltd., | 0.30% | 5ml | eye drops | per ml | KES 16.50 |
| Gentacil | Globe Pharmacy Ltd., | Globe Pharmacy Ltd., | 0.30% | 10ml | eye drops | per ml | KES 18.00 |
| Gentamicin more info | |
|---|---|
| Mode Of Action | irreversibly binds to 30s sub-unit of bacterial ribosomes; blocks recognition step in protein synthesis and causes growth inhibition. |
| Drug Indication | Sensitive UTI, RTI, severe systemic infections, bone and tissue infections, eye infections. |
| Precautions | Avoid use with potent diuretics, nephrotoxic and neurotoxic drugs, impaired renal functions, myasthenia gravis. |
| Contra-Indications | Pregnancy and lactation, myasthenia gravis |
| Side Effects | Vestibular and auditory damage, nephrotoxicity; rarely, hypomagnesaemia on prolonged therapy, antibiotic-associated colitis, stomatitis; also reported, nausea, vomiting, rash, blood disorders. |
| Dosage | Adult: Multiple daily dose regimen, by intramuscular or by slow intravenous injection over at least 3 minutes or by intravenous infusion, 3-5 mg/kg daily (in divided doses every 8 hours. Endocarditis (in combination with other antibacterials, adult 1 mg/kg every 8 hours Once daily dose regimen, by intravenous infusion, initially 5-7 mg/kg, then adjust according to serum-gentamicin concentration. By intrathecal injection, seek specialist advice, 1 mg daily (increased if necessary to 5 mg daily). Child: Neonatal sepsis, extended interval dose regimen by slow intravenous injection or intravenous infusion. Neonate less than 32 weeks postmenstrual age 4-5 mg/kg every 36 hours. Neonate 32 weeks and over postmenstrual age 4-5 mg/kg every 24 hours. Multiple daily dose regimen by slow intravenous injection. Neonate less than 29 weeks postmenstrual age 2.5 mg/kg every 24 hours. Neonate 29-35 weeks postmenstrual age 2.5 mg/kg every 18 hours Neonate over 35 weeks postmenstrual age 2.5 mg/kg every 12 hours. Septicaemia, meningitis and other CNS infections, biliary-tract infection, acute pyelonephritis, endocarditis, pneumonia in hospital patients, adjunct in listerial meningitis. Once daily dose regimen (not for endocarditis or meningitis) by intravenous infusion. Child 1 month-18 years initially 7 mg/kg, then adjusted according to serum-gentamicin concentration. Multiple daily dose regimen by intramuscular or by slow intravenous injection over at least 3 minutes. Child 1 month-12 years 2.5 mg/kg every 8 hours Child 12-18 years 2 mg/kg every 8 hours. Pseudomonal lung infection in cystic fibrosis:By slow intravenous injection over at least 3 minutes or by intravenous infusion. Child 1 month-18 years 3 mg/kg every 8 hours. Bacterial ventriculitis and CNS infection (supplement to systemic therapy) By intrathecal or intraventricular injection, seek specialist advice Neonate seek specialist advice Child 1 month-18 years:1 mg daily (increased if necessary to 5 mg daily). Note: Onl |
| Pregnancy Category | Category D |
| Pregnancy Category Description | Drugs, which have caused, are suspected to have caused, or may be expected to cause an increased rise in the frequency of malformations or irreversible damage. These drugs may also have adverse pharmacological effects required required |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Aminoglycosides |